Last reviewed · How we verify
MS-553
At a glance
| Generic name | MS-553 |
|---|---|
| Sponsor | MingSight Pharmaceuticals, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL (PHASE1, PHASE2)
- MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema (PHASE1)
- A Study Of The Selective PKC-β Inhibitor MS- 553 (PHASE1, PHASE2)
- A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma (PHASE1, PHASE2)
- A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL (PHASE1, PHASE2)
- A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MS-553 CI brief — competitive landscape report
- MS-553 updates RSS · CI watch RSS
- MingSight Pharmaceuticals, Inc portfolio CI